Search Videos by Topic or Participant
Browse by Series:

Clinical Experience With Panobinostat in Multiple Myeloma

Insights From:Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL; Jatin J. Shah, MD, The University of Texas MD Anderson Cancer Center; Andrew Sp
Published: Friday, Jan 15, 2016


In a patient who has had a prior autologous stem cell transplant and is progressing on lenalidomide maintenance therapy, the triplet of panobinostat, bortezomib, and dexamethasone is a good option, explains Jatin J. Shah, MD. In this setting, the benefits with panobinostat and bortezomib are maximized, as progression-free survival improves by approximately 4 months with the triplet versus bortezomib and dexamethasone alone.

Another option is retreatment with bortezomib plus carfilzomib, since patients treated with bortezomib have a certain comfort level with carfilzomib, says Shah. This combination is also an option for later lines of therapy, he notes.

A patient who has relapsed early following upfront bortezomib and autologous stem cell transplantation can receive the panobinostat triplet, notes Maria-Victoria Mateos, MD, PhD. One patient in her practice experienced this type of relapse and had a short duration of response with subsequent lenalidomide-based therapy. She was then included in a clinical trial with the panobinostat triplet, explains Mateos, and achieved a complete response. Five years later, the patient is still on single-agent panobinostat and the drug is well tolerated.

Several clinical trials are exploring the use of panobinostat in multiple myeloma, says Andrew Spencer, MD, including a trial in patients who had a suboptimal response with frontline therapy. The data show that about half of these patients have a further reduction in tumor burden with panobinostat. At his practice, some of the younger patients have achieved complete remissions.
Slider Left
Slider Right


In a patient who has had a prior autologous stem cell transplant and is progressing on lenalidomide maintenance therapy, the triplet of panobinostat, bortezomib, and dexamethasone is a good option, explains Jatin J. Shah, MD. In this setting, the benefits with panobinostat and bortezomib are maximized, as progression-free survival improves by approximately 4 months with the triplet versus bortezomib and dexamethasone alone.

Another option is retreatment with bortezomib plus carfilzomib, since patients treated with bortezomib have a certain comfort level with carfilzomib, says Shah. This combination is also an option for later lines of therapy, he notes.

A patient who has relapsed early following upfront bortezomib and autologous stem cell transplantation can receive the panobinostat triplet, notes Maria-Victoria Mateos, MD, PhD. One patient in her practice experienced this type of relapse and had a short duration of response with subsequent lenalidomide-based therapy. She was then included in a clinical trial with the panobinostat triplet, explains Mateos, and achieved a complete response. Five years later, the patient is still on single-agent panobinostat and the drug is well tolerated.

Several clinical trials are exploring the use of panobinostat in multiple myeloma, says Andrew Spencer, MD, including a trial in patients who had a suboptimal response with frontline therapy. The data show that about half of these patients have a further reduction in tumor burden with panobinostat. At his practice, some of the younger patients have achieved complete remissions.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x